The next big break would be the approval of OXYCONTIN IR Generic which Perdue is trying to block.Same, I purchased 2 M at about 0.04 cents. Even with the current revenue and profit I think the stock should be trading at about 40 cents.
I am not sure any gov' group is going to rule on Oxy anytime soon, buts its awesome you got in at the same price as me! I do think this stock should be worth more, just going to keep having good quarterly reports!
@runningrobert I really like how the game rewards patient, methodical approaches instead of running nonstop while dodge-rolling all over the place. 😅 Nice find!!
Thank you for checking out my channel! Your game rocks, as it feels like when I was playing heroes of might and magic, soooo all that nostalgia plus all the news things you have done to make it different!
Protalix does not sell to the end customer. Chiesi is a private company that is competing with entranched drugs, so they will not publish sales. $11.2M was recorded as cash with the revenue not recognized yet. thats why the revenue shortfall. cash received on shipment to Chiesi (my understanding per agreement) while revenues get recognized according to Chiesi's metrics. Add back that revenue and the company actually made money in the quarter. fyi, $11.2M of API should be equivalent to atleast $50M of product in sales value for Chiesi. That bodes well as far as Chiesi's confidence and outlook.
Yes, they sell Chiesi and Chiesi gives them the 15% royalty upfront for sales, They have received 6.4M and a 3M (in 2023 for sales), which should equal 9.4 /.15 which is almost 63M in total sales. Now since I dont know the agreement for how much API Chiesi has to buy I cant equate that into sales until they get the royalty sale Chiesi does not give number but we get no update from mang. about how sales are doing, if they are increasing, % of insurance that covers the drug ext..... Since they might not buy for another quarter or 2 (per the CC) it means that sales are not coming in strong out of the gate, (if they dont sell any till 4Q), That would indicate less then 20-40M sold for 5Q (I dont know how much they need to keep on hand but its prob around 20-30M in the channel), which is a slow start. Which could change but mang is not giving any information about that.
Thanks for the great rundown on GERN! Could you do something similar with VRSSF, an AI company out of Toronto, Canada? Their AI work looks to be potentially game changing, as far as I can tell… Thanks! 🙏
Thank you for watching, So I cover Biotech because I wont in the industry which I feel gives me an edge for investing, however I know nothing about AI so it just wouldn't fit what I am doing. Sorry
Just look at the path make me thinking right aways of The Colonists game. This game feel like a minimalist version of that game lol Preferbably build road as short as possible to increase transport speed. Also all road should have equal length so there is no bottle-neck.
So I had to look up that game for the reference, and your right it def looks like it, with some differences! I might have to wait for a steam sale for it
This seems like a very interesting game. I'm surprised that I was only the 8th view, because this video is very well made. Also i find it a bit strange that their staple crop is apples and not something like wheat or rice like it was for the vast majority of most ancient civilisations.
Thank you for your comments, The apple thing is prob just because it is easy, thought I guess rice would be to, they add wheat and bread later in the game
I gought in 80 cents. Long term, what do you think the ceiling is for this company? I am asking because I am trying to figure out if I should sell at $2 or keep it for highter returns in two or three years. Thanks for the great information.
The best price wont be determined until ROLVEDON value is truly discovered. So if they end up selling around 100M a year, based on the expenses, I would expect 3-4 to be the high, if they can push it to 400M a year, then 15-20 could be the high. I am very curious how the 2Q will go, because that will give us a good indication of growth, since looking at 1Q are rough since there are insurance changes and such that can affects sales. I do expect a decent ramp up of sales so that why I said we would see 2 this year!
I can get on board with that, they do things a little bit different, however first thing I thought is that its pretty close! I am still enjoying it though!
At the moment there aren't really any whispers about any kind of takeover, I believe a company would want to see approval and the realization of sales before anything like that comes up
I enjoyed most of it, the ending had me confused until I had to look it up! The game was super awesome besides that. I think it took me about 3.5-4 hours total, so def a nice game you can finish in a week if you have the time!
Yeah 100% so we can say there was some significant sales last Aug/Sep, this was post data and a open period for insiders, and they sold which is what they do in most companies. Now saying that, even though there was some big sales, most of the main people still own over 5M in shares. Come Nov when they started the application process for approval, insiders would not be allowed to trade the stock because they might have inside information on requests from the FDA. The blackout day for them will prob go until the approval date, which is why we havent seen any buys
So I have been looking into FGEN, the pancreatic cancer trials are def worth a look, but cancer drugs can be fairly difficult to see passing results, esp since at some point everyone dies, and they didnt have any "whales" (people who survive on the drugs for yearssss) to help boost up the number for the earlier trials However the trials still could pass, and it def looks like the market has factored in it not passing, I have bought some options in it, but the company needs to get the spending under control before I could really think about buying a decent amount
In the midst of all the bearish aspect that's surrounding it, SEC filling stated that Director Deveer Robert recently bought 6,000 shares at $2.11 on the 11/04/2024. I reckon, there is something they know which aren't obvious to the public.
A 12,000 dollar stock purchase isnt that big for a guy worth about 200 million. I dont consider the purchase of any significance, now if he had bought 6 million shares then yes....something big
So a little history on this company. They trialed oral for pain (hip & knee) and it failed. They trialed the drug for post op pain and it passed but there was no market for it so they dropped it. They trialed oral for atopic dermatitis and it failed. They trialed the drug for oral Kidney and they cancelled that trial. They trialed the drug for IV CKD and it passed and they partnered with Fresenius who owns 50% of the US dialysis clinics in the USA and told investors that there were about 200,000 patients waiting for this drug but after 18 months only managed to sell enough to treat about 2500 patients. They have now informed investors that there will be no meaningful income from that source. They have essentially failed in every endeavor with this drug even failing when they had successful trials. This last trial is their one and only hope and it's an oral trial. Every oral trial they have tried has failed. They are running out of money and they are probably about to get delisted or do a reverse split.
Great video! I think this is one of LPCN's most interesting drugs in their pipeline at the moment in terms of the potential to draw a partner. Obesity drugs are a rapidly growing space and this drug's is very unique in its ability to maintain moderate fat loss on top of increasing lean body mass. I really believe this drug can work as an adjunct therapeutic to these stronger obesity drugs, because the main limitation of all of the major obesity drugs on the market is that they attack muscle mass as much as they attack fat which does decrease total body weight but it does not really improve body composition the way 2401 has shown the potential ability to in these early stages. I think any of these major obesity drug companies should be jumping on a partnership with LPCN once they lay out a path to approval with the FDA.
I believe there is def potential for a possible long term investment, the questions is going to be, what does the FDA want to see in future trials, and who is going to partner with them?
Great video! Could you possibly do another report on LPCN they just announced some groundbreaking results in terms of obesity management with their drug LPCN 2401
The simple one is below a dollar, haha I dont think we will see that. I am going to follow the quarterly reports to see if I can get any information about how much longer they will have a clinical hold, (and get the "real" expenses for the year)
Excellent until you get to the end and inexplicably suggest a stock dilution. FUD? Why would they need to do that? You are aware of past dilutions and of outstanding warrants? Yes? No? SCYX has the cash on hand and they have the milestones. And they have Scy-247 and other fungerps as yet unveiled. So no need for new capital. GSK does the production now. GSK does the marketing now. SCYX only needs to continue the clinical trials and FDA submissions. So capital is covered already.
I gotta look at it from every point, and the question is the cash enough to get them that sweet 100M payout, and if they can get the clinical trial started again quickly, then yes, however..... if it takes longer its going to be close, and most companies like to have a year cash on hand (some run it much tighter), Its not FUD, it is something that might happen, and really depend on when they get the trial restarted
Very good video my friend! Seems like 1154 is the biggest catalyst for this company right now. I have been in this stock since 2020 and ive seen a lot of highs and lows, I decided to average down my holdings earlier today and have already seen some gains from the hype for the topline data. 1148 I think is still the crown jewel but getting partnership is a major hurdle like you pointed out. For anyone potentially trying to go in this is not a good swing play in my opinion but a good long term one, the company is cash rich at the moment but is still speculative and the stock is heavily manipulated. It reacts very oddly to news, I have seen it decrease initially off of good news and look dead, then skyrocket a couple days later. This company has so much potential to grow a lot and I think its a good play long term.
Your right the company has so much potential, which is why I still cover it, and I hope 1154 can start the official turnaround! 1148 is sad since the data was soooo good, but now its just stuck in the mud!
